Drugs & Targets FDA approves Tevimbra + chemo for first-line treatment of gastric and GEJ cancers January 10, 2025Vol.51 No.01
Drugs & Targets FDA approves Unloxcyt for metastatic or locally advanced cutaneous squamous cell carcinoma January 10, 2025Vol.51 No.01
Drugs & Targets FDA approves Ryoncil for steroid-refractory acute graft versus host disease in pediatric patients January 10, 2025Vol.51 No.01
Drugs & Targets FDA approves Opdivo and Opdivo Qvantig for subcutaneous injection January 10, 2025Vol.51 No.01
Drugs & Targets FDA grants accelerated approval to encorafenib with cetuximab and mFOLFOX6 for metastatic colorectal cancer with a BRAF V600E mutation January 10, 2025Vol.51 No.01
Drugs & Targets EC approves Opdivo + Yervoy as first-line treatment for MSI-H or dMMR metastatic CRC January 10, 2025Vol.51 No.01
Drugs & Targets FDA clears IND application for Recursion’s LSD1 inhibitor REC-4539 January 10, 2025Vol.51 No.01
Drugs & Targets MD Anderson, AmMax Bio announce agreements to develop immunotherapy for MRD-positive cancers December 13, 2024Vol.50 No.46
Drugs & Targets PolyPid announces collaboration with ImmunoGenesis in solid tumors December 13, 2024Vol.50 No.46
